{"id":34909,"date":"2016-11-29T12:45:43","date_gmt":"2016-11-29T04:45:43","guid":{"rendered":"http:\/\/www.chinamoneynetwork.com\/?p=58365"},"modified":"2016-11-29T12:45:43","modified_gmt":"2016-11-29T04:45:43","slug":"chinas-sdic-leads-260m-series-d-round-in-innovent-biologics","status":"publish","type":"post","link":"https:\/\/www.chinalegalblog.com\/en\/2016\/11\/29\/chinas-sdic-leads-260m-series-d-round-in-innovent-biologics\/","title":{"rendered":"China's SDIC Leads $260M Series D Round In Innovent Biologics"},"content":{"rendered":"<img width=\"300\" height=\"248\" src=\"http:\/\/www.chinamoneynetwork.com\/wp-content\/uploads\/medicine-copy-2-2.jpg\" class=\"attachment-large size-large wp-post-image\" alt=\"medicine-copy-2\" style=\"display: block; margin: auto; margin-bottom: 5px;\" \/>A fund managed by Chinese state-owned investment entity State Development &#038; Investment Corporation (SDIC) has led a US$260 million series D funding round in Chinese biopharmaceutical company Innovent Biologics, according to Chinese media reports. New investors China Life Investment Holding Co., Ltd., Taikang Insurance Co., Ltd., Ping An Insurance, as well as existing investors Legend [&#8230;]<p><br>Visit <a href=\"http:\/\/www.chinamoneynetwork.com\/\" title=\"China Money Network\"><b>ChinaMoneyNetwork.com<\/b><\/a> for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter <a href=\"http:\/\/www.twitter.com\/chinamoneypod\" title=\"Follow China Money Network on Twitter\">@chinamoneypod<\/a> subscribe to all episodes on <a href=\"http:\/\/www.itunes.com\/podcast?id=451002399\" title=\"Download and listen to China Money Podcast on iTunes\">iTunes<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"248\" src=\"http:\/\/www.chinamoneynetwork.com\/wp-content\/uploads\/medicine-copy-2-2.jpg\" alt=\"medicine-copy-2\">A fund managed by Chinese state-owned investment entity State Development &amp; Investment Corporation (SDIC) has led a US$260 million series D funding round in Chinese biopharmaceutical company Innovent Biologics, according to Chinese media reports. New investors China Life Investment Holding Co., Ltd., Taikang Insurance Co., Ltd., Ping An Insurance, as well as existing investors Legend [&hellip;]<\/p>\n<p>Visit <a href=\"http:\/\/www.chinamoneynetwork.com\/\" title=\"China Money Network\"><b>ChinaMoneyNetwork.com<\/b><\/a> for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter <a href=\"http:\/\/www.twitter.com\/chinamoneypod\" title=\"Follow China Money Network on Twitter\">@chinamoneypod<\/a> subscribe to all episodes on <a href=\"http:\/\/www.itunes.com\/podcast?id=451002399\" title=\"Download and listen to China Money Podcast on iTunes\">iTunes<\/a>.<\/p>\n","protected":false},"author":167,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[477,807,194,1621,1623],"tags":[8903,7593],"class_list":["post-34909","post","type-post","status-publish","format-standard","hentry","category-investment","category-investments","category-news-chinese-law","category-private-equity","category-venture-capital","tag-biologics","tag-fund-news"],"_links":{"self":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/34909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/users\/167"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/comments?post=34909"}],"version-history":[{"count":2,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/34909\/revisions"}],"predecessor-version":[{"id":34966,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/34909\/revisions\/34966"}],"wp:attachment":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/media?parent=34909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/categories?post=34909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/tags?post=34909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}